Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

Overview of attention for article published in Lancet Oncology, June 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#33 of 6,937)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 86 news outlets
blogs: 2 blogs

twitter: 110 X users
video: 1 YouTube creator

Readers on

mendeley: 28 Mendeley

Summary News Blogs X YouTube

So far, Altmetric has seen 153 X posts from 110 X users, with an upper bound of 448,647 followers.

RT @YJanjigianMD: The next chapter in the epic story of HER2. Two trials in HER2+ BTC by @HardingJJMD @GABOUALFA & group. Data on 1) anti-…

19 Jan 2024

Reply Repost Favourite

RT @ucl_discovery: Open Access UCL Research: Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract can…

13 Jan 2024

Reply Repost Favourite

RT @ucl_discovery: Open Access UCL Research: Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract can…

09 Jan 2024

Reply Repost Favourite

Open Access UCL Research: Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study https://t.co/raWz5CaLBZ

08 Jan 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 149 additional X posts.